Interim Results From The Phase I Deplethink Trial Evaluating The Infusion Of A Nkg2d Car T-Cell Therapy Post A Non-Myeloablative Conditioning In Relapse Or Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Patients